Urothelial carcinoma in COVID-19: lessons from a pandemic and their impact on clinical practice.
Georges Abi TayehNour KhalilMarwan AlkassisFouad AounChady WakedElie NemrPublished in: Future oncology (London, England) (2021)
The COVID-19 pandemic has modified the management of urothelial carcinoma (UC). Eighteen months after the onset of the pandemic, a scoping narrative review was able to state that radical cystectomy for UC should not be delayed beyond 10 weeks when neoadjuvant chemotherapy (NAC) was administered and 12 weeks when it was not. NAC should be considered when imminent chemotherapy cannot be performed. Early cystectomy should not be delayed when indicated for patients with high-risk non-MIBC. Patients with non-MIBC should still receive their induction doses of intravesical instillations. Diagnostic cystoscopy should not be deferred in symptomatic patients. Surgical management of upper tract urothelial carcinoma (UTUC) allows for a wider deferral interval.
Keyphrases
- neoadjuvant chemotherapy
- coronavirus disease
- sars cov
- locally advanced
- clinical practice
- transcription factor
- end stage renal disease
- lymph node
- newly diagnosed
- ejection fraction
- sentinel lymph node
- squamous cell carcinoma
- respiratory syndrome coronavirus
- peritoneal dialysis
- early stage
- robot assisted
- genome wide analysis
- patient reported
- urinary tract